IBIO

Value Q1, 25Q2, 25Q3, 25Q4, 25 TTM Total revenue 100 K000 100 K Gross profit 100 K000 100 K Operating expenses 6.05 M9.45 M8.37 M11.38 M 35.24 M Selling/general/admin expenses 2.5 M5.17 M5.11 M-2.18 M 10.6 M Research & development 3.55 M4.28 M3.25 M8.56 M 19.64 M Operating income -5.95 M-9.45 M-8.37 M-11.38 M -35.14 M Non-Operating Income, Total 231 K452 K635 K779 K 2.1 M Interest expense, net of interest capitalized 36 K41 K22 K-46 K 53 K Non-Operating Income, excl. Interest Expenses 231 K452 K635 K779 K 2.1 M Unusual income/expense ———— — Pretax income -5.76 M-9.03 M-7.75 M-10.55 M -33.1 M Equity in earnings ———— — Taxes 0000 0 Non-controlling/minority interest ———— — After tax other income/expense ———— — Net income before discontinued operations -5.72 M-8.99 M-7.73 M-10.6 M -33.04 M Discontinued operations ———— — Net income -5.72 M-8.99 M-7.73 M-10.6 M -33.04 M Dilution adjustment ———— — Preferred dividends ———— — Diluted net income available to common stockholders -5.67 M-8.99 M-7.73 M-10.65 M -33.04 M Basic earnings per share (Basic EPS) -0.11-0.09-0.06-0.06 -0.32 Diluted earnings per share (Diluted EPS) -0.11-0.09-0.06-0.06 -0.32 Average basic shares outstanding 52.98 M99.13 M119.6 M104.06 M — Diluted shares outstanding 52.98 M99.13 M119.6 M104.06 M — EBITDA 3.24 M-9.3 M-8.21 M-11.25 M -25.52 M EBIT -5.95 M-9.45 M-8.37 M-11.38 M -35.14 M Cost of revenue ———— — Other cost of goods sold ———— — Depreciation & amortization (cash flow) 9.19 M146 K152 K132 K 9.62 M